Please login to the form below

Not currently logged in
Email:
Password:

Teva completes Cephalon purchase

Teva Pharmaceutical has acquired US-based biopharmaceutical company Cephalon for about $6.8bn following approval from the European Union

Teva Pharmaceutical has acquired US-based biopharmaceutical company Cephalon for about $6.8bn following approval from the European Union (EU).

The EU had demanded that Teva sell off its generic version of Cephalon's narcolepsy drug, Provigil (modafinil), to enable another company to own a competitor product.

Cephalon is now a wholly owned subsidiary of Teva, with Cephalon to receive $81.50 per share of common stock.

Teva said the combined company is to have a presence in over 60 countries. As individual companies, the combined revenue of Teva and Cephalon for the period July 2010 to June 2011 was around $20bn.

Shlomo Yanai, president and CEO of Teva, said the purchase was part of the Israel-based company's attempt to build its branded pharmaceuticals business through diversification and expansion of its product portfolio and pipeline.

17th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics